This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Eterna LLC | |
|---|---|
| Name | Eterna LLC |
| Type | Private |
| Industry | Biotechnology |
| Founded | 2014 |
| Headquarters | Philadelphia, Pennsylvania |
| Products | RNA design platform, synthetic biology services |
| Employees | 120 (2024) |
Eterna LLC is a biotechnology company focused on computational RNA design, synthetic biology, and distributed citizen science. Founded in 2014, the company developed platforms for RNA folding, design optimization, and laboratory validation that engage both professional researchers and crowdsourced players. Eterna LLC collaborates with academic institutions, technology firms, and nonprofit organizations to translate computational puzzles into experimentally verified nucleic acid constructs.
Eterna LLC emerged from research projects at Princeton University, Stanford University, and the University of California, Santa Cruz laboratories that investigated RNA folding and citizen science. Early prototypes built on methods pioneered in the RNA World Hypothesis discourse and experiments related to ribozymes and riboswitches. Initial funding and seed partnerships included grants and awards from organizations such as the National Science Foundation, the Gordon and Betty Moore Foundation, and the Simons Foundation. Public launches leveraged conferences at institutions like Cold Spring Harbor Laboratory, presentations at TED, and demonstrations at BIO International Convention events.
Key milestones include a first large-scale online puzzle campaign inspired by mechanisms explored in CRISPR-Cas9 research and computational strategies similar to those in the Human Genome Project. The company expanded its laboratory capacity after partnerships with commercial laboratories in the Boston biotechnology cluster and collaborations with researchers at Harvard University and Massachusetts Institute of Technology. Over time, Eterna LLC adapted game mechanics influenced by projects such as Foldit and citizen science models like Zooniverse.
Eterna LLC offers a suite of products and services centered on RNA and nucleic acid design. Principal offerings include a web-based RNA design platform, cloud computational tools, and wet-lab synthesis and validation services. The platform integrates algorithms comparable to those used in Rosetta (software), with visualization paradigms akin to interfaces developed at Broad Institute initiatives.
Commercial services encompass custom design of aptamers, siRNA constructs, and mRNA elements for vaccine research, delivered alongside experimental assays executed in partnership with contract research organizations in the San Francisco Bay Area and Research Triangle Park. Educational and outreach products include curricula adapted for programs at the Museum of Science, Boston and workshops at the National Institutes of Health training events. The company also supplies data analytics for academic labs at institutions such as Yale University and Columbia University.
Eterna LLC's technology stack combines inverse RNA folding algorithms, Monte Carlo sampling, and machine learning models trained on experimental datasets produced in-house and through collaborative trials with the European Molecular Biology Laboratory and the Salk Institute. Computational pipelines use optimization heuristics inspired by methods from Simulated Annealing studies and probabilistic models akin to those in Hidden Markov Model applications to biological sequence analysis.
Research efforts have focused on improving prediction of secondary and tertiary RNA structures, leveraging experimental techniques such as high-throughput sequencing assays similar to SHAPE-Seq and chemical mapping protocols used in studies at Cold Spring Harbor Laboratory. Projects explored structure-function relationships relevant to ribosome engineering, thermodynamic modeling as applied in Nearest-Neighbor thermodynamic models, and design rules for synthetic riboswitches tested in cell-free systems influenced by work at Wyss Institute.
Eterna LLC is organized as a privately held company with a board composed of investors, academic founders, and industry executives drawn from technology and life sciences sectors. Leadership has included executives with prior roles at startups incubated within Y Combinator, senior scientists recruited from Howard Hughes Medical Institute-affiliated labs, and advisers from entities such as Pfizer and Novartis.
The company maintains R&D teams distributed between offices in Philadelphia and satellite labs near Cambridge, Massachusetts and San Diego. Governance practices reflect models used by small-cap biotechnology firms active in the NASDAQ ecosystem, with advisory committees for scientific ethics and data governance formed with contributors from American Association for the Advancement of Science convenings.
Eterna LLC has cultivated partnerships across academia, industry, and nonprofit sectors. Collaborative agreements have been announced with research groups at University of Pennsylvania, commercial alliances with synthetic biology firms in the Biotech Bay Area, and pilot projects with public health partners similar to programs run by Gavi, the Vaccine Alliance. The company has presented at international meetings including EMBO seminars and exhibited at CES to demonstrate citizen science interfaces.
Market positioning emphasizes niche services in RNA design for universities, biotech startups, and pharmaceutical research groups, drawing clients who previously engaged vendors like Twist Bioscience and Integrated DNA Technologies. Strategic alliances include data-sharing initiatives modeled after collaborations at the Allen Institute and joint development projects with contract manufacturers in Singapore.
Eterna LLC operates within a regulatory landscape shaped by agencies such as the Food and Drug Administration, the Office of Biotechnology Activities, and international authorities like the European Medicines Agency. Compliance efforts address laboratory biosafety standards developed under frameworks similar to those promulgated by the Centers for Disease Control and Prevention and institutional review processes comparable to Institutional Review Board requirements at universities.
Legal considerations have included intellectual property management related to sequence designs, licensing negotiations influenced by precedent cases in biotechnology patent law from the United States Court of Appeals for the Federal Circuit, and data protection obligations informed by regulations akin to General Data Protection Regulation. The company has engaged legal counsel with experience in matters before the United States Patent and Trademark Office and in contract disputes resolved through arbitration panels similar to those convened by the International Chamber of Commerce.
Category:Biotechnology companies